In vitro transcytosis assay
By using MDCK cells expressing heterologous FcRn gene in vitro to measure the transcytosis of mAb under physiological pH conditions, the problem of difficult prediction of mAb pharmacokinetic characteristics in the prior art is solved, and the clearance and half-life of mAb are achieved Accurate assessment provides cost-effective screening tools.
Patent Information
- Application Number
- CN201980054147.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-08-17
- Filing Date
- 2019-08-16
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2039-08-16
AI Technical Summary
The prior art is difficult to accurately predict the pharmacokinetic characteristics of therapeutic monoclonal antibodies (mAbs) in humans, especially the clearance rate and half-life, and the existing in vitro assays lack the restrictiveness that can effectively simulate in vivo conditions. Animal model development Time-consuming and expensive, making it difficult to achieve PK behavior conversion from animals to humans.
The transcytosis of the target molecule was measured under physiological pH using Martin-Dabbi canine kidney cells (MDCK cells) expressing the heterologous FcRn gene, and the transcytosis of the target molecule was measured by enzyme-linked immunosorbent assay. Techniques such as assay (ELISA), liquid scintillation count (LSC), or fluorescence reader systems measure the transcellular transport of molecules and evaluate their in vivo clearance and half-life.
This method can accurately evaluate the in vivo clearance and half-life of mAbs, provide cost-effective screening tools, support leading selection and optimization processes, reduce dependence on animal models, and improve drug development efficiency.
Smart Images

Figure CN112567243B_ABST
Abstract
Description
[0001] Cross-references to related patent applications
[0002] This application claims priority to U.S. Provisional Patent Application Serial No. 62 / 719,402 filed on August 17, 2018, the contents of which are incorporated herein by reference in their entirety. Technical Field
[0003] The present disclosure relates to methods and compositions useful for measuring transcytosis of molecules. In particular, the present disclosure relates to in vitro receptor-dependent transcytosis assays for assessing in vivo pharmacokinetic characteristics, e.g., clearance rates and / or half-lives of molecules that interact with FcRn (e.g., therapeutic antibodies, Fc fusion molecules, and molecules linked to albumin). Background Art
[0004] Therapeutic monoclonal antibodies (mAbs) have become a major class of pharmaceutical products in the world due to their proven effectiveness in the treatment of various diseases and their desirable pharmacological properties. One of the favorable pharmacological properties of mAb drugs is that their circulation half-life is generally long. Extending the half-life of biotherapeutic products can reduce the frequency of drug administration and / or reduce the dosage, which reduces the cost of care, improves patient compliance and reduces concentration-dependent cytotoxicity / adverse events.
[0005] Significant progress has been made in understanding the pharmacokinetic (PK) characteristics of mAb drugs in animals and humans. Although many mAb drugs show similar PK behaviors similar to endogenous IgG, it is often observed that mAb drugs have obvious heterogeneity in the nonspecific clearance rate in the human body. Therefore, in the drug development process, evaluating and selecting clinical candidate drugs with ideal PK characteristics is an important early step. Extensive techniques involving computer simulation, in vitro analysis and in vivo analysis have been used to evaluate and / or predict the PK behavior of mAb in the human body (Dostalek et al., 2017, MAbs 9 (5): 756-766). However, the conversion of PK data from animals to humans and from in vitro determination to in vivo readings is still elusive for drug developers (Vugmeyster et al., 2012, World J Biol Chem 3 (4): 73-92). Furthermore, although some animal models such as human FcRn transgenic mice (Avery, 2010) and non-human primates (Deng et al., 2011, Drug Metab Dispos 38(4):600-605) have been successfully used to reflect the PK of mAbs in humans, these studies are usually time-consuming, expensive and involve animal sacrifice.
[0006] There are many complexities in predicting the PK of human mAbs from animal studies and in vitro assays. Target-mediated drug disposition (TMDD) is known to influence the dose-dependent PK behavior of mAbs, resulting in nonlinear distribution and elimination. In the absence of TMDD, mAbs are expected to exhibit linear elimination and nonspecific clearance rates, reflecting the target-independent nature of molecule-specific drug catabolism. Nonspecific clearance of mAbs is primarily mediated by lysosomal degradation in the reticuloendothelial system, with the neonatal Fc receptor (FcRn)-mediated salvage pathway playing a major role. Structurally, FcRn is a heterodimer composed of a transmembrane heavy chain (FCGRT) homologous to class I major histocompatibility complex (MHC)-like molecules and a soluble light chain, beta2 microglobulin (B2M). FcRn binds to the Fc domain of endogenous IgG at acidic pH (less than 6.5) but only minimally at neutral or alkaline pH (greater than 7.0). This unique property enables FcRn to protect Fc-containing molecules from degradation by binding to them in acidic endosomes after they have been taken up into the cell, transporting them back to the cell surface, and releasing them into the circulation at physiological pH. In contrast, internalized molecules that do not bind to FcRn are directed to lysosomes for degradation (see Figure 6 and Roopenian et al., Nat Rev Immunol. 2007 Sep;7(9):715-25).
[0007] Although the role of FcRn in extending the half-life of Fc-containing proteins is widely recognized (Ward, 2015), the lack of correlation between FcRn binding and PK of mAb drugs in humans has been reported (Suzuki, 2010; Zheng, 2011; Hotzel, 2012), indicating that binding affinity to FcRn is not the sole determinant of the elimination rate of Fc-containing proteins. Given the function of FcRn in intracellular trafficking, the kinetics of endosomal sorting and trafficking of Fc-containing molecules / FcRn complexes may affect the overall efficiency of FcRn-mediated salvage mechanisms and, therefore, the rate of nonspecific clearance of molecules. In addition, cellular uptake via pinocytosis or endocytosis and degradation processes within lysosomes may also play a role in determining the rate and extent of mAb degradation (Gurbaxani, 2013). Finally, biochemical features such as charge / pI and glycosylation pattern have been reported to affect mAb disposition (Datta-Mannan, 2015; Igawa, 2010; Khawli, 2010). These molecular features may themselves affect mAb structure, thereby altering the “real” interaction with FcRn in vivo, or may contribute to nonspecific cell surface binding, thereby altering the mode / rate of internalization and the relative proportions of FcRn-mediated intracellular trafficking pathways (including recycling and transcytosis).
[0008] A variety of in vitro assays have been developed to simulate IgG Fc-FcRn interactions. The inherent limitations of many of these assays are the lack of non-specific interactions involving cells, plasma proteins and extracellular matrix (ECM) components and intracellular transport parameters relevant to the recycling, transcytosis and lysosomal degradation of mAbs. Preferably, in vitro assays for predicting mAb clearance will be able to assess the combined effects of electrostatic interactions, cellular uptake of Abs, interactions with FcRn and intracellular transport of molecules. However, considering the various factors that affect mAb disposal in vivo, it is difficult to develop a simple in vitro assay that can accurately and consistently predict the PK behavior of mAb drugs.
[0009] The development of animal models also faces challenges. Although animal models such as human FcRn transgenic mouse models (Avery, 2010) and non-human primate models (Deng, 2011) have been successfully used to reflect the PK of mAbs in humans, these studies are usually time-consuming, expensive, and involve animal sacrifice. In addition, the translation of PK behavior from animal studies to humans is not simple and easy, partly due to species differences in FcRn binding, TMDD, and induction of anti-drug immune responses (Liu, 2018).
[0010] Therefore, there remains a need for methods to predict the in vivo PK properties of therapeutic molecules (e.g., clearance or half-life) that can be performed in a short time and at a reasonable cost to aid in the evaluation and selection of therapeutic molecules. Summary of the invention
[0011] The present disclosure relates to methods and compositions that can be used to measure the transcytosis of target molecules. In particular, the present disclosure relates to in vitro receptor-dependent transcytosis assays for assessing in vivo pharmacokinetic characteristics, such as clearance rates and / or half-lives of molecules that interact with FcRn (e.g., therapeutic antibodies, Fc fusion molecules, and molecules linked to albumin).
[0012] In certain embodiments, the present disclosure relates to methods for determining pharmacokinetic (PK) parameters of target molecules. For example, such methods may include determining a measure of transcytosis of a molecule or molecules by a cell or cells under physiological pH conditions. In certain embodiments, the PK parameter is a measure of the in vivo clearance of the molecule. In certain embodiments, the PK parameter is a measure of the in vivo half-life of the molecule.
[0013] In certain embodiments, a measure of transcytosis used in conjunction with the methods disclosed herein is a rate of transcytosis. In certain embodiments, a measure of transcytosis is a measure of the amount of a molecule or molecules that are transcytosed.
[0014] In certain embodiments, the measure of transcytosis is determined by measuring the transcytosis of one or more molecules from a solution in a first chamber to a solution in a second chamber, wherein the first chamber and the second chamber are separated by a cell monolayer, and the solution in each chamber is at physiological pH. In certain embodiments, one or more cells are Martin-Darby canine kidney (MDCK) cells. In certain embodiments, the cell comprises at least one heterologous gene. In certain embodiments, at least one heterologous gene is selected from the group consisting of FCGRT gene and B2M gene. In certain embodiments, the cell expresses heterologous cell surface proteins. In certain embodiments, the heterologous cell surface proteins comprise neonatal Fc receptors (FcRn). In certain embodiments, measuring the transcytosis of molecules includes using enzyme-linked immunosorbent assay (ELISA), liquid scintillation counting (LSC), quantitative PCR or fluorescence reader systems. In certain embodiments, the methods disclosed herein further include: determining the in vivo clearance rate of the molecule based on the number of molecules measured.
[0015] In certain embodiments of the present disclosure, the target molecule is a molecule that naturally binds to FcRn. In certain embodiments, the molecule is engineered to bind to FcRn. In certain embodiments, the molecule is an Fc-containing molecule. In certain embodiments, the Fc-containing molecule is a receptor Fc fusion molecule. In certain embodiments, the molecule is an antibody. In certain embodiments, the antibody is a monoclonal antibody. In certain embodiments, the molecule is an albumin-containing molecule.
[0016] In certain embodiments, the present disclosure relates to a method for measuring the transcellular transport of multiple single molecules or multiple different molecules, comprising: a) introducing multiple single molecules or multiple different molecules into a first chamber of two chambers, wherein the first chamber is separated from the second chamber by one or more cells, and wherein the first chamber and the second chamber each have a physiological pH value; and b) measuring the number of molecules transcytosed from the first chamber to the second chamber. In certain embodiments, the first chamber comprises a monolayer of cells. In certain embodiments, the cells are Martin-Darby canine kidney (MDCK) cells. In certain embodiments, the cells comprise at least one heterologous gene. In certain embodiments, at least one heterologous gene is selected from the group consisting of FCGRT genes and B2M genes. In certain embodiments, the cells express heterologous cell surface proteins. In certain embodiments, the heterologous cell surface proteins comprise neonatal Fc receptors (FcRn). In certain embodiments, measuring the number of molecules transported across cells comprises using enzyme-linked immunosorbent assays (ELISA), liquid scintillation counting (LSC), quantitative PCR, or fluorescence reader systems. In certain embodiments, the methods disclosed herein further comprise: determining the in vivo clearance rate of the molecule based on the number of molecules measured.
[0017] In certain embodiments, the present disclosure relates to a method for determining the in vivo clearance rate of a molecule, comprising: a) introducing a molecule into a first chamber of two chambers, wherein the first chamber is separated from the second chamber by one or more cells, and wherein the first chamber and the second chamber each have a physiological pH value; b) measuring the number of molecules transcytosed from the first chamber to the second chamber; and c) based on the measured number of molecules, determining the in vivo clearance rate of the molecule. In certain embodiments, the first chamber includes a monolayer of cells. In certain embodiments, the cell is an MDCK cell. In certain embodiments, the cell comprises at least one heterologous gene. In certain embodiments, at least one heterologous gene is selected from the group consisting of FCGRT gene and B2M gene. In certain embodiments, the cell expresses a heterologous cell surface protein. In certain embodiments, the heterologous cell surface protein comprises a neonatal Fc receptor (FcRn). In certain embodiments, measuring the number of molecules transported across cells comprises using an enzyme-linked immunosorbent assay (ELISA), liquid scintillation counting (LSC), quantitative PCR or a fluorescence reader system. In certain embodiments, the molecule is a molecule that naturally binds to FcRn.
[0018] In certain embodiments, the present disclosure relates to a determination for measuring the transcellular transport of multiple molecules. For example, but not limited to, the determination may include using a first chamber and a second chamber, each of which has a physiological pH value, wherein the first chamber receives multiple molecules, is configured to transport molecules transcellularly to the second chamber, and the transcellular transport of multiple molecules is measured. In certain embodiments, the first chamber includes a monolayer of cells. In certain embodiments, the cell is an MDCK cell. In certain embodiments, the cell includes at least one heterologous gene. In certain embodiments, at least one heterologous gene is selected from the group consisting of FCGRT gene and B2M gene. In certain embodiments, the cell expresses heterologous cell surface proteins. In certain embodiments, the heterologous cell surface protein includes a neonatal Fc receptor (FcRn). In certain embodiments, the number of molecules measuring transcellular transport includes using an enzyme-linked immunosorbent assay (ELISA), liquid scintillation counting (LSC), quantitative PCR or a fluorescence reader system. In certain embodiments, the determination further includes: determining the in vivo clearance rate of the molecule based on the measured number of molecules.
[0019] In certain embodiments, the present disclosure relates to a determination system comprising: a first chamber and a second chamber, wherein the first chamber and the second chamber each have a physiological pH; a monolayer of cells positioned in the first chamber so that the cells can mediate transcytosis of molecules introduced into the first chamber to the second chamber; and a detector for detecting the presence of molecules in the second chamber. In certain embodiments, the cells are MDCK cells. In certain embodiments, the cells comprise at least one heterologous gene. In certain embodiments, at least one heterologous gene is selected from the group consisting of FCGRT genes and B2M genes. In certain embodiments, the cells express heterologous cell surface proteins. In certain embodiments, the heterologous cell surface proteins comprise neonatal Fc receptors (FcRn). In certain embodiments, measuring the number of molecules transported across cells comprises using enzyme-linked immunosorbent assays (ELISA), liquid scintillation counting (LSC), quantitative PCR, or fluorescence reader systems. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 Schematic diagrams of certain embodiments of the transcytosis assays of the present disclosure are depicted.
[0021] Figure 2A to Figure 2B Depicted is the expression of human FcRn heavy chain and β2-microglobulin on the transfected clonal MDCK cell line 305-6. Flow cytometry histograms of B2M (A) and FCGRT (B) cell surface expression of WT and 305-6 cells.
[0022] Figure 3A to Figure 3E Scatter plots are shown depicting the relationship between clearance in humans (rate in mK / Kg / day) and either transcytosis value (A; concentration in ng / mL), FcRn binding affinity at pH 6.0 (B; Kd in M), or BVELISA score (C). In addition, the clearance rate of mAbs in cynomolgus monkeys (rate in mK / Kg / day) is plotted against the transcytosis value (D) or clearance rate in humans (E). A linear regression model was fitted to the data, and both the equation and R-squared value are given.
[0023] Figure 4A to Figure 4C Shown are the relationship between clearance in humans and transcytosis in MDCK cells (A) or MDCK-hFcRn cells (B), and the relationship between binding to MDCK-hFcRn cells and transcytosis in MDCK-hFcRn cells (C).
[0024] Figure 5A to Figure 5CShown are the relationships between clearance in humans and charge (A), pI (B), or transcytosis output (C) of the mAbs.
[0025] Figure 6 Schematic diagram depicting the potential fate of internalized molecules. DETAILED DESCRIPTION
[0026] In practicing the presently disclosed subject matter, many conventional techniques in molecular biology, microbiology, cell biology, biochemistry, and immunology are used. These techniques are described in more detail in, for example, Molecular Cloning: a Laboratory Manual, 3rd edition, JF Sambrook and DW Russell, eds., Cold Spring Harbor Laboratory Press, 2001; Recombinant Antibodies for Immunotherapy, Melvyn Little, ed., Cambridge University Press, 2009; Oligonucleotide Synthesis, MJ Gait, ed., 1984; Animal Cell Culture, RI Freshney, ed., 1987; Methods in Enzymology, American Academy Press; Current Protocols in Molecular Biology, FM Ausubel et al., eds., 1987, and periodically updated; PCR: The Polymerase Chain Reaction, Mullis et al., eds., 1994; A Practical Guide to Molecular Cloning, 1996. Practical Guide to Molecular Cloning, Perbal Bernard V., 1988; Phage Display: A Laboratory Manual, Barbas et al., 2001. The contents of these references and other references containing standard protocols, including manufacturer's product instructions, are widely known and relied upon by those skilled in the art and are hereby incorporated by reference as part of the present disclosure.
[0027] 1. Definition
[0028] Unless otherwise defined, all technical terms, symbols and other scientific terms used herein are intended to have the meanings commonly understood by those skilled in the art to which the present disclosure belongs. In some cases, terms with commonly understood meanings are defined herein for clarity and / or ease of reference, and the inclusion of such definitions herein should not be construed as representing a significant difference from what is generally understood in the prior art.
[0029] As used herein, the terms "comprises," "including," "having," "having," "may," "containing," and variations thereof are intended to be open-ended transitional phrases, terms, or words that do not exclude the possibility of additional actions or structures. Unless expressly provided otherwise, the singular forms "a," "an," and "the" include plural referents. The present disclosure also contemplates other embodiments "comprising," "consisting of," and "consisting essentially of" the embodiments or elements set forth herein, whether or not expressly set forth.
[0030] As used herein, the term "about" or "approximately" means within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, in accordance with practice in the art, in some embodiments, "about" can mean 3 or more than 3 standard deviations. Alternatively, in some embodiments, "about" can mean a range of up to 20%, up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within a certain order of magnitude of a certain value, such as within 5 times or within 2 times.
[0031] As used herein, the terms "culture medium" and "cell culture medium" refer to a nutrient source for growing or maintaining cells. As will be appreciated by those skilled in the art, a nutrient source may contain components required for cell growth and / or survival, or may contain components that contribute to cell growth and / or survival. Vitamins, essential or non-essential amino acids (e.g., cysteine and cystine) and trace elements (e.g., copper) are examples of culture medium components. Any culture medium provided herein may also be supplemented with any one or more of insulin, plant hydrolysates, and animal hydrolysates.
[0032] As used herein, the phrase "pharmacokinetic (PK) parameter" refers to any of a variety of PK parameters known in the art, including but not limited to clearance (CL), half-life (t 1 / 2 ), area under the curve (AUC), volume of distribution (V d ) and maximum / minimum plasma concentration (C max / C min ).
[0033] As used herein, the term "clearance rate" refers to the rate at which a molecule or polypeptide is removed from the bloodstream.
[0034] As used herein, the term "physiological pH" refers to a pH of about 6.5 to about 8.0. In certain embodiments, the physiological pH value is any value between about 6.5 to about 8.0, for example, about 6.6, about 6.7, about 6.8, about 6.9, about 7.0, about 7.1, about 7.2, about 7.3, about 7.4, about 7.5, about 7.6, about 7.7, about 7.8, or about 7.9, or any range within the range of about 6.5 to about 8.0.
[0035] "Culturing" cells means contacting the cells with a cell culture medium under conditions suitable for the survival and / or growth and / or proliferation of the cells.
[0036] As used herein, "molecule" generally refers to a molecule that is the subject of an assay. For example, but not limitation, the molecule may be any molecule that naturally binds to FcRn or has been engineered to bind to FcRn, such as, but not limited to, an albumin-containing molecule, a molecule engineered to bind to FcRn via a peptide tag or other amino acid sequence, an antibody, an antibody fragment, or a polyclonal or monoclonal antibody as defined below. Such polypeptides, proteins, antibodies, antibody fragments, or polyclonal or monoclonal antibodies may include non-naturally occurring substances, including, but not limited to, non-naturally occurring amino acids, non-amino acid linkers, or spacers, and may include conjugates with other components, such as small molecules or macromolecular therapeutic agents.
[0037] As used herein, "polypeptide" generally refers to peptides and proteins having more than about ten amino acids. The polypeptides may be homologous to the host cell or may be exogenous, meaning that they are heterologous, i.e., foreign, to the host cell utilized, such as human proteins produced by Chinese hamster ovary cells, or yeast polypeptides produced by mammalian cells. In certain embodiments, mammalian polypeptides (polypeptides originally derived from mammalian organisms) are used, and in certain embodiments, the polypeptides of the present disclosure are secreted directly into the culture medium.
[0038] The term "protein" means an amino acid sequence whose chain length is sufficient to produce a higher level of tertiary and / or quaternary structure. This is to distinguish it from "peptides" or other small molecular weight drugs that do not have such structures. Typically, the protein herein will have a molecular weight of at least about 15-20 kD, and in certain embodiments, at least about 20 kD. Examples of proteins encompassed in the definition herein include all mammalian proteins, particularly therapeutic proteins and diagnostic proteins, such as therapeutic antibodies and diagnostic antibodies, and are generally proteins containing one or more disulfide bonds, including multi-chain polypeptides containing one or more interchain and / or intrachain disulfide bonds.
[0039] The term "antibody" is used herein in the broadest sense and encompasses various antibody structures, including but not limited to multispecifics (eg, bispecific antibodies) and antibody fragments that exhibit the desired antigen-binding activity.
[0040] As used herein, "antibody fragment", "antigen-binding portion" of an antibody (or simply "antibody portion"), or "antigen-binding fragment" of an antibody refers to a molecule other than an intact antibody that contains a portion of an intact antibody that binds an antigen and / or epitope. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); and antibody fragments formed from multispecific antibodies (e.g., bispecific antibodies).
[0041] As used herein, the term "monoclonal antibody" or "mAb" refers to an antibody obtained from a substantially homogeneous antibody population, that is, except for possible variant antibodies (e.g., containing naturally occurring mutations or produced during the production of monoclonal antibody preparations, such variants are usually present in small amounts), each antibody comprising the population is identical and / or binds to the same epitope. Contrary to polyclonal antibody preparations that typically include different antibodies for different determinants (epitopes), each monoclonal antibody in a monoclonal antibody preparation is directed to a single determinant on an antigen. Therefore, the modifier "monoclonal" indicates that the characteristic of an antibody is obtained from a substantially homogeneous antibody population, and should not be interpreted as requiring antibodies to be produced by any particular method. For example, the monoclonal antibodies used according to the current disclosed subject matter can be prepared by a variety of techniques, including but not limited to hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of a human immunoglobulin locus, such methods and other exemplary methods for preparing monoclonal antibodies are described herein.
[0042] The term "hybridoma" refers to a hybrid cell line produced by fusing an immortal cell line of immune origin with an antibody-producing cell. The term encompasses the progeny of heterogeneous hybrid myeloma fusions, which are the result of fusion of a murine myeloma cell line with a human cell and subsequently with a plasma cell, commonly known as a tri-source hybridoma cell line. In addition, the term is intended to include any immortalized hybrid cell line that produces antibodies, such as, for example, a quadroma. See, e.g., Munson et al., Anal. Biochem., 537:3053 (1983).
[0043] As used herein, the term "cell" refers to animal cells, mammalian cells, cultured cells, host cells, recombinant cells, and recombinant host cells. Such cells are typically cell lines obtained from mammalian tissue or derived from mammalian tissue, and are able to grow and survive when placed in a culture medium containing appropriate nutrients and / or growth factors.
[0044] As used herein, the term "heterologous gene" refers to a gene encoding a protein that is foreign to the host cell being utilized, such as a gene encoding a human protein produced in Chinese hamster ovary cells, or a gene encoding a yeast polypeptide produced in mammalian cells.
[0045] 2. Overview
[0046] The present disclosure relates to methods and compositions that can be used to measure the transcytosis of target molecules. In particular, the present disclosure relates to in vitro receptor-dependent transcytosis assays for evaluating PK parameters such as clearance rate and / or half-life of therapeutic antibody molecules. As disclosed in detail herein, the transcytosis of target molecules (e.g., mAbs) measured by the methods of the present disclosure is highly correlated with the PK properties of cells (such as the in vivo clearance rate of the molecule). Therefore, the claimed methods for measuring the transcytosis of target molecules can be used to evaluate the in vivo clearance rate and other PK parameters such as half-life of the molecule. In certain embodiments, the method includes measuring the transcellular transport of multiple identical target molecules from a first chamber to a second chamber, wherein the first chamber and the second chamber each have a physiological pH value (e.g., pH = about 7.4).
[0047] Thus, for example, in one aspect, provided herein is a cell-based assay using MDCK cells stably expressing human FcRn and β2-microglobulin genes to measure the transcytosis efficiency of monoclonal antibody (mAb) drugs under conditions associated with the FcRn-mediated IgG salvage pathway. This transcytosis assay is performed under physiological pH conditions and is designed to assess the results of the combined effects of non-specific binding of IgG to cells, its uptake via pinocytosis, its pH-dependent interaction with FcRn, and the kinetics of intracellular transport and sorting processes. As described in more detail in the "Examples", the inventors evaluated 49 mAbs, including 27 commercially available mAb drugs, and demonstrated a significant correlation between the clearance rate in humans and the readings from an assay such as disclosed herein. The expression of FcRn is necessary to promote the transcytosis of mAbs in the assay and directly contributes to the observed correlation. Furthermore, an assay such as provided herein is able to correctly rank the clearance rates of charge or glycosylation variants of Fc-containing molecules in preclinical species. The results provided in the Examples support the utility of the assay disclosed herein as a cost-effective and animal-saving screening tool for evaluating mAb-based drug candidates during lead selection and optimization and process development for desired pharmacokinetic properties.
[0048] 3. Transcytosis Assay
[0049] Transcytosis refers to the vesicular transport of macromolecules from one side of a cell to the other and is a strategy used by multicellular organisms to selectively move materials between two environments without changing the unique composition of those environments. Transcytosis is a mechanism of transcellular transport in which cells enclose extracellular material in invaginations of the cell membrane to form a vesicle, which is then moved across the cell, allowing the material to be ejected through the opposite cell membrane by the reverse process.
[0050] In a typical FcRn-mediated transcytosis assay, MDCK cells expressing FcRn are grown to confluence on a filter membrane in a trans-well plate, and a pH gradient is created by filling the inner chamber with an acidic assay buffer (pH < 6.0) and the outer chamber with an alkaline assay buffer (pH > 7.4) prior to the assay. The rationale for this assay design is to take advantage of the pH-dependent binding properties of FcRn by facilitating cellular uptake of the test molecule by binding to FcRn on the cell surface at acidic pH and releasing the test molecule at alkaline pH, both of which improve the robustness and sensitivity of the assay. However, based on the studies described herein, the inventors have come to recognize that such assays are inherently flawed for predictive assessment of the PK behavior of mAbs. Since transfected cells typically express high levels of FcRn on the cell surface, and the test antibodies are incubated with the cells in an acidic environment, it can be determined that the test antibodies with high binding affinity for FcRn at acidic pH readily bind to FcRn and enter the cells via FcRn-mediated endocytosis. However, the inventors determined that this is contrary to what occurs in vivo, where antibodies minimally bind to cell surface FcRn at physiological pH, and cellular uptake of mAbs is primarily mediated by nonspecific fluid phase pinocytosis. As a result, the inventors determined that the output of the pH gradient transcytosis assay is severely affected by the FcRn binding affinity of the antibody at acidic pH, and therefore it is impossible to fully reflect the contribution of other factors that affect PK, such as electrostatic interactions and intracellular transport parameters. In addition, it was further determined that artificial pH conditions are inherently harmful to cells, which limits the duration of the assay and may potentially produce additional assay artifacts.
[0051] Therefore, and as described in more detail in the "Examples", the inventors have developed a different method to measure transcytosis as a basis for subsequently accurately determining a measure of PK parameters such as clearance and / or half-life. Thus, for example, in certain embodiments, the present disclosure provides a method for measuring transcellular transport of a plurality of single molecules or a plurality of different molecules, comprising: a) introducing a plurality of single molecules or a plurality of different molecules into a first chamber, wherein the first chamber is separated from a second chamber by a cell or cells, and wherein the first chamber and the second chamber each have a physiological pH value; and b) measuring the number of molecules transcytosed from the first chamber to the second chamber. In certain embodiments, the physiological pH value is about 6.5 to about 8.0. In certain embodiments, the physiological pH value is any value between about 6.5 and about 8.0, for example, about 6.6, about 6.7, about 6.8, about 6.9, about 7.0, about 7.1, about 7.2, about 7.3, about 7.4, about 7.5, about 7.6, about 7.7, about 7.8, or about 7.9, or any range within the range of about 6.5 to about 8.0. In certain embodiments, the pH of each chamber can be different, as long as both chambers have a physiological pH. For example, but not limited to, the pH of the first chamber can be 6.5, and the pH of the second chamber can be 8.0, or vice versa. In certain embodiments, the physiological pH can be about 7.4.
[0052] In certain embodiments, the present disclosure provides a method for determining a pharmacokinetic (PK) parameter of a molecule, comprising determining a measure of transcytosis of a molecule or molecules by a cell or cells under physiological pH conditions. In certain embodiments, the PK parameter may be a measure of the in vivo clearance of a molecule. In certain embodiments, the PK parameter may be a measure of the in vivo half-life of a molecule. In certain embodiments, the measure of transcytosis may be the rate of transcytosis. In certain embodiments, the measure of transcytosis may be a measure of the amount of a molecule or molecules transcytosed. In certain embodiments, the measure of transcytosis may be determined by measuring the transcytosis of a molecule or molecules from a solution in a first chamber to a solution in a second chamber, wherein the first chamber and the second chamber are separated by a cell monolayer, and the solution in each chamber is at physiological pH. In certain embodiments, the cell or cells may be a Martin-Darby canine kidney (MDCK) cell. In certain embodiments, the cell comprises at least one heterologous gene. In certain embodiments, at least one heterologous gene may be selected from the group consisting of FCGRT gene and B2M gene. In certain embodiments, the cell may express a heterologous cell surface protein. In certain embodiments, the heterologous cell surface protein may include a neonatal Fc receptor (FcRn). In certain embodiments, measuring the transcytosis of a molecule may include using an enzyme-linked immunosorbent assay (ELISA), liquid scintillation counting (LSC), quantitative PCR, or a fluorescence reader system. In certain embodiments, the method of the present disclosure may further include: determining the in vivo clearance of the molecule based on the measured number of molecules. In certain embodiments, the molecule may be a molecule that naturally binds to FcRn or a molecule that is engineered to bind to FcRn. In certain embodiments, the molecule may be an Fc-containing molecule. In certain embodiments, the molecule may be an antibody. In certain embodiments, the antibody may be a monoclonal antibody. In certain embodiments, the molecule may be an albumin-containing molecule. In certain embodiments, the physiological pH is about 6.5 to about 8.0. In certain embodiments, the physiological pH value is any value between about 6.5 and about 8.0, for example, about 6.6, about 6.7, about 6.8, about 6.9, about 7.0, about 7.1, about 7.2, about 7.3, about 7.4, about 7.5, about 7.6, about 7.7, about 7.8, or about 7.9, or any range within the range of about 6.5 to about 8.0. In certain embodiments, the pH of each chamber can be different, as long as both chambers have a physiological pH. For example, but not limited to, the pH of the first chamber can be 6.5, and the pH of the second chamber can be 8.0, or vice versa. In certain embodiments, the physiological pH can be about 7.4.
[0053] In certain embodiments, the assay comprises seeding a cell or cells in cell growth medium onto a 96-well Trans-well plate having medium in an inner chamber and an outer chamber, removing the medium from the inner chamber, adding the test molecule to the inner chamber, incubating in a tissue culture incubator for a period of time, collecting the medium from the outer chamber and quantifying the transcytosed test molecule. In certain embodiments, the cells may be cultured at a rate of about 1×10 5 The density of cells / well is inoculated in cell growth medium. In certain embodiments, the cell growth medium can be high glucose DMEM supplemented with 10% FBS, 100 units of penicillin / streptomycin and 5 μg / mL of puromycin. In certain embodiments, the culture medium in the inner chamber can be 100 μL, and the culture medium in the outer chamber can be 200 μL. In certain embodiments, the cells can be used the next day after plating. In certain embodiments, the test molecule can be added to a final concentration of about 100 μg / mL (0.67 μM) and incubated in a tissue culture incubator at 37°C for 24 hours. In certain embodiments, fluorescein (fluorescein CH, dilithium salt; Sigma Aldrich; St.Louis MO) can be prepared in cell growth medium and can be added in the last 90 minutes of the 24-hour assay incubation. In certain embodiments, the passive passage level of fluorescein during the assay can be calculated by dividing the fluorescent signal in the sample from the outer chamber by the fluorescent signal in the inner chamber. In certain embodiments, transcytosis results from wells that exhibit greater than 0.1% passive passage of Lucifer Yellow in the outer chamber may be discarded.
[0054] In certain embodiments, a test molecule can be added to the outer chamber of a trans-well assay, and transcytosis can be detected by measuring the amount of the test molecule present in the inner chamber after an appropriate incubation period. In certain embodiments, the test molecule is transcytosed from the chamber exposed to the apical membrane of the cell to the chamber exposed to the basolateral membrane of the cell.
[0055] In certain embodiments, the present disclosure provides a method for determining or predicting the in vivo clearance rate of one or more molecules, comprising: a) introducing a molecule into a first chamber of two chambers, wherein the first chamber is separated from the second chamber by one or more cells, and wherein the first chamber and the second chamber each have a physiological pH value; and b) measuring the number of molecules transcytosed from the first chamber to the second chamber. In certain embodiments, the physiological pH value is about 6.5 to about 8.0. In certain embodiments, the physiological pH value is any value between about 6.5 to about 8.0, for example, about 6.6, about 6.7, about 6.8, about 6.9, about 7.0, about 7.1, about 7.2, about 7.3, about 7.4, about 7.5, about 7.6, about 7.7, about 7.8, or about 7.9, or any range within the range of about 6.5 to about 8.0. In certain embodiments, the pH of each chamber can be different, as long as both chambers have a physiological pH. For example, but not limitation, the pH of the first chamber may be 6.5, while the pH of the second chamber may be 8.0, or vice versa. In certain embodiments, the physiological pH may be about 7.4.
[0056] In certain embodiments, the present disclosure provides an assay for measuring transcellular transport of a plurality of identical molecules or a plurality of different molecules, comprising a first chamber and a second chamber, each of which has a physiological pH, wherein the first chamber receives a plurality of molecules and is configured to allow transcytosis of the molecules to the second chamber. In certain embodiments, the physiological pH is about 6.5 to about 8.0. In certain embodiments, the physiological pH is any value between about 6.5 to about 8.0, for example, about 6.6, about 6.7, about 6.8, about 6.9, about 7.0, about 7.1, about 7.2, about 7.3, about 7.4, about 7.5, about 7.6, about 7.7, about 7.8, or about 7.9, or any range within the range of about 6.5 to about 8.0. In certain embodiments, the pH of each chamber may be different, as long as both chambers have a physiological pH. For example, but not limited to, the pH of the first chamber may be 6.5, while the pH of the second chamber may be 8.0, and vice versa. In certain embodiments, the physiological pH may be about 7.4.
[0057] In certain embodiments, the present disclosure provides an assay for determining or predicting the in vivo clearance of one or more molecules, comprising a first chamber and a second chamber, each of the first chamber and the second chamber having a physiological pH, wherein the first chamber receives a plurality of molecules and is configured to allow transcytosis of the molecules to the second chamber. In certain embodiments, the physiological pH is about 7.4.
[0058] In certain embodiments, the first chamber may include a monolayer of cells. In certain embodiments, the cells used in the assay are selected from the list provided in Section 3 below. In certain embodiments, the cells employed in the assay are MDCK cells.
[0059] In certain embodiments, the cells used in the methods of the present disclosure may comprise at least one heterologous gene. In certain embodiments, the at least one heterologous gene may be selected from the group consisting of a FCGRT gene and a B2M gene.
[0060] In certain embodiments, the cells used in the methods of the present disclosure may express cell surface proteins. In certain embodiments, the cell surface proteins comprise Fc receptors (FcR). In certain embodiments, the cell surface proteins comprise neonatal Fc receptors (FcRn).
[0061] In certain embodiments, the molecule may be labeled or unlabeled. Non-limiting examples of labeled molecules include 3 H-labeled molecules, fluorescently labeled molecules, or radioactive isotopes (e.g., I-125 and P-32).
[0062] In certain embodiments, the methods of the present disclosure include measuring the number of molecules transported across cells. In certain non-limiting embodiments, measuring the number of molecules transported across cells can be performed by enzyme-linked immunosorbent assay (ELISA), liquid scintillation counting (LSC), quantitative PCR, fluorescence reader system, confocal microscope or live cell imaging system.
[0063] In certain embodiments, the present disclosure provides an FcRn-dependent cell-based assay for measuring transcytosis of mAbs (e.g., IgG mAbs) by MDCK cells expressing human FcRn and B2M under conditions similar to the FcRn-mediated IgG salvage pathway. In certain embodiments, the output of the assay not only relates to Fc-FcRn interactions under physiological conditions, but also to nonspecific binding, cellular uptake, sorting, and intracellular transport processes associated with the in vivo PK behavior of mAbs.
[0064] In certain embodiments, the present disclosure provides methods for correlating transcytosis measured using assays described herein with reported clearance rates of molecules, such as polypeptides, having different structural, functional, and pharmacological properties in humans.
[0065] In certain embodiments, expression of FcRn may be required to promote transcytosis of mAbs in the assay and contribute to the observed correlation between transcytosis and clearance. In certain embodiments, the assays described in the present disclosure are capable of ranking the clearance rates of charge or glycosylation variants of Fc-containing molecules in preclinical material. In certain embodiments, the assays described in the present disclosure can be used as time-saving, cost-saving, and animal-saving tools for evaluating mAb-based drug candidates during lead selection and optimization, as well as process development for desired pharmacokinetic properties.
[0066] In certain embodiments, the present disclosure provides cell-based assays that measure the transcytosis efficiency of mAb drugs under physiologically relevant conditions. In certain embodiments, MDCK cells stably expressing human FcRn and β2-microglobulin genes are used in conjunction with the assays described herein.
[0067] In certain embodiments, the disclosure provides assays performed at physiological pH in normal cell culture medium supplemented with fetal bovine serum, which provides bovine albumin that is known to bind to human FcRn (Chaudhury C. et al., 2003, J. Exp. Med. 197, 315-322).
[0068] In certain embodiments, the disclosure provides assays in which a molecule is taken up by a cell via non-specific pinocytosis, interacts with human FcRn in the presence of albumin, and crosses the cell under conditions relevant to an FcRn-mediated mechanism of action.
[0069] In certain embodiments, the present disclosure provides assays for determining or predicting the clearance of mAbs in humans due to the ability of the assay to assess the combined effects of non-specific binding to cells, uptake via pinocytosis, pH-dependent interaction with FcRn, and dynamic changes in intracellular trafficking and sorting processes.
[0070] In certain embodiments, the present disclosure provides an assay for correlating the resulting transcytosis output with the clearance rate of the mAb in humans. In certain embodiments, the output of the assay of the present disclosure can be the concentration (ng / mL) of the transcytotic molecule in the culture medium of the outer chamber, and the reportable value of the assay can be the average concentration of at least 2 replicate wells from the same plate. In certain embodiments, the output of the assay can be a measure of the transcytosis rate or a measure of the relative transcytosis of the transcytotic molecule relative to the control molecule.
[0071] In certain embodiments, the selection of test molecules for the assays of the present disclosure can be based on the availability of clinical grade materials and human in vivo clearance data from reliable sources, such as, but not limited to, prescription information, published reports based on population PK models, or internal clinical trials that generate linear PK data. In certain embodiments, the use of clinical grade materials can ensure that the quality of the test materials can be consistent with those used in clinical studies that generate human PK data.
[0072] In certain embodiments, the assays described herein can be used as tools for in vitro assessment of potential burden in nonspecific clearance of drug candidates to support lead selection and optimization, with the goal of ranking drug candidates and reducing the number of molecules tested in animal models.
[0073] In certain embodiments, the assays described herein can be used to support the investigation of mAbs that exhibit poor or atypical PK behavior, or to support the development of novel mAb drugs with transcytosis properties relevant to specific applications, such as crossing the blood-brain barrier to enhance brain exposure, or enhancing disposition in the tumor microenvironment to improve tumor targeting.
[0074] In certain embodiments, the assays described in the present disclosure can be used to develop improved mechanism-based PK models to support the design of optimal doses and dosing regimens in clinical studies.
[0075] In certain embodiments, the assays described herein can be used to demonstrate correlation between in vitro readouts and in vivo PK data for a test molecule.
[0076] In certain embodiments, the test molecule can be an antibody. In certain embodiments, the antibody can be a monoclonal antibody or a polyclonal antibody. In certain embodiments, the antibody can have different structural compositions (chimeric, humanized and fully human). In certain embodiments, the antibody can be composed of different heavy and light chain sequences (IgG1, IgG2 and IgG4 heavy chains, κ and λ light chains). In certain embodiments, the antibody can recognize different types of targets (membrane-bound and soluble). In certain embodiments, the antibody can exert different therapeutic mechanisms of action (excitatory, antagonistic and cytotoxic). In certain embodiments, the antibody can and does be given to the patient by different routes (e.g., iv, im and sc).
[0077] In certain embodiments, the test molecule may carry engineered mutations that may alter effector function (such as, but not limited to, atezolizumab, durvalumab), enable bispecific half-antibody association (such as, but not limited to, emizumab), or stabilize the IgG4 Fab arm (such as, but not limited to, nivolumab, pembrolizumab).
[0078] In certain embodiments, the test molecule may be a mAb that exhibits extreme FcRn binding affinity. In certain embodiments, the correlation between the observed transcytosis readings and clearance in humans is applicable to a variety of mAbs carrying typical Fc regions. In certain embodiments, the test molecule may be an antibody engineered to have altered FcRn binding activity. In certain embodiments, the test molecule may be an albumin-containing molecule, or any molecule engineered to bind to FcRn via a peptide tag or recombinant protein. In certain embodiments, the test molecule may be a molecule that naturally binds to FcRn. In certain embodiments, the test molecule may be a molecule engineered to bind to FcRn.
[0079] In certain embodiments, the assays described herein can be used to indicate whether expression of human FcRn is required for efficient transcytosis in a transcytosis assay.
[0080] In certain embodiments, assays of the present disclosure can be used to detect and / or indicate that interaction with FcRn contributes to the observed correlation between transcytosis readout and clearance of the test molecule.
[0081] In certain embodiments, the assays disclosed herein can be used for binding analysis of a test molecule to a receptor. In certain embodiments, the receptor can be an FcRn receptor. In certain embodiments, the test molecule can be a mAb.
[0082] In certain embodiments, assays of the invention can be used to assess the contribution of multiple factors, such as, but not limited to, the kinetics of internalization, sorting and intracellular transport, and the impact of exocytosis on the overall efficiency of the test molecule recovery process.
[0083] In certain embodiments, the assays of the present disclosure can be used to identify and / or detect multiple parameters involved in the FcRn-mediated salvage pathway for use in determining or predicting the PK of a mAb.
[0084] In certain embodiments, the assays of the present disclosure can be used to detect the correlation of in vitro transcytosis of a molecule with in vivo clearance. In certain embodiments, the assays of the present disclosure can be used to detect the correlation of in vitro transcytosis of a molecule with in vivo clearance compared to BV ELISA or Fv charge / pI.
[0085] In certain embodiments, the assays of the present disclosure can be used to assess and / or explore the effects of glycosylation on the in vivo distribution and catabolism of a mAb. In certain embodiments, the molecule may be a glycoform variant.
[0086] In certain embodiments, the assays disclosed herein can be used to assess the effects of adding sialic acid to a molecule on intracellular transport parameters. In certain embodiments, the assays disclosed herein can be used to analyze the involvement of additional mechanisms in the in vivo clearance of high mannose and high sialylated glycoform variants of the molecule.
[0087] In certain embodiments, the assays of the present disclosure can be used as tools to study FcRn-mediated transcytosis as a mechanism of Ab elimination associated with its PK.
[0088] In certain embodiments, the assays of the invention can be used as tools to study and elucidate the molecular mechanisms that control the distribution of FcRn-complexed IgG.
[0089] In certain embodiments, the assays of the present disclosure can provide outputs that reflect the target-independent, nonspecific clearance mechanism of mAbs with typical FcRn binding affinity in humans.
[0090] In certain embodiments, the assays of the present disclosure can be used to analyze a diverse panel of various Fc-containing molecules and respond to factors known to affect PK.
[0091] In certain embodiments, the assays of this embodiment can be used to dissect factors involved in transcytosis assays in order to understand how these factors correlate with in vivo clearance and define the quantitative nature of this correlation.
[0092] In certain embodiments, the assays of the present disclosure can be used to explore the distribution of pinocytosed mAbs between recycling, transcytosis, and degradation pathways in various cell types / tissue compartments, as well as the molecular mechanisms controlling such distribution in cells involved in IgG clearance.
[0093] In certain embodiments, the present invention relates to a transcytosis assay system. For example, but not limited to, such a system may include: a first chamber and a second chamber, wherein the first chamber and the second chamber each have a physiological pH; and a monolayer of cells positioned in the first chamber so that the cells can mediate transcytosis of molecules introduced into the first chamber to the second chamber; and a detector for detecting the presence of molecules in the second chamber. In certain embodiments, the assay system disclosed herein employs a monolayer of MDCK cells. In certain embodiments, the assay system disclosed herein employs cells comprising at least one heterologous gene. In certain embodiments, the assay system disclosed herein employs cells comprising at least one heterologous gene selected from the group consisting of FCGRT genes and B2M genes. In certain embodiments, the assay system disclosed herein employs cells expressing heterologous cell surface proteins. In certain embodiments, the assay system disclosed herein employs cells expressing heterologous cell surface proteins, wherein the heterologous cell surface proteins comprise neonatal Fc receptors (FcRn). In certain embodiments, the assay systems disclosed herein can measure the number of molecules transported across cells via the use of enzyme-linked immunosorbent assay (ELISA), liquid scintillation counting (LSC), quantitative PCR, or a fluorescence reader system.
[0094] 4. Cells
[0095] Suitable cells for use in the assays of the present disclosure include prokaryotic or eukaryotic cells as described herein.
[0096] In certain embodiments, vertebrate cells can also be used. Non-limiting examples of useful mammalian cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells, as described, for example, in Graham et al., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK); mouse Sertoli cells (TM4 cells, as described, for example, in Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK); Buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor cells (MMT 060562); TRI cells (as described, for example, in Mather et al., Annals NYAcad.Sci.383:44-68 (1982)); MRC 5 cells; and FS4 cells. Additional non-limiting examples of useful mammalian cell lines include Chinese hamster ovary (CHO) cells, including DHFR-CHO cells (Urlaub et al., Proc.Natl.Acad.Sci.USA 77:4216 (1980)). In certain embodiments, the methods of the present disclosure may use hybridoma cells. For example, but not limitation, hybrid cell lines may be of any species, including humans and mice. In certain embodiments, the methods of the present disclosure may use primary and constructed endothelial and / or epithelial cells.For example, but not limited to, endothelial and / or epithelial cells can be caco-2, T-84, HMEC-1, MHEC 2.6, HUVEC and induced pluripotent stem cell (iPSC) derived cells (Lidington, EA, DL Moyes, et al. (1999). "A comparison of primary endothelial cells and endothelial cell lines for studies of immune interactions." Transpl Immunol 7(4): 239-246; Yamaura, Y., BD Chaparron, et al. (2016). "Functional Comparison of Human Colonic Carcinoma Cell Lines and Primary Small Intestinal Epithelial Cells for Investigations of Intestinal Drug Permeability and First-Pass Metabolism." Drug Metab Dispos 44(3): 329-335).
[0097] In certain embodiments, the cell used for the disclosed method may include nucleic acids encoding molecules such as receptors. In certain embodiments, nucleic acids may be present in one or more vectors (e.g., expression vectors). One type of vector is a "plasmid", which refers to a circular double-stranded DNA loop to which additional DNA segments can be connected. Another type of vector is a viral vector, in which additional DNA segments can be connected to a viral genome. Some vectors can replicate autonomously in cells (e.g., bacterial vectors and episomal mammalian vectors with bacterial replication origins) into which they are introduced. After being introduced into the cell, other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of the cell, thereby replicating with the host genome. In addition, some vectors (expression vectors) can guide the expression of nucleic acids operably connected thereto. Typically, expression vectors useful in recombinant DNA technology are typically in the form of plasmids (vectors). Other non-limiting examples of expression vectors used in the present disclosure include viral vectors (e.g., replication-defective retroviruses, adenoviruses, and adeno-associated viruses) that play equivalent functions.
[0098] In certain embodiments, nucleic acids encoding molecules such as receptors can be introduced into cells. In certain embodiments, nucleic acids can be introduced into cells by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a virus or phage vector containing a nucleic acid sequence, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. In certain embodiments, the cell is a eukaryotic cell, for example, an MDCK cell.
[0099] 5. Trans-well assay
[0100] Suitable trans-well assays employed in the methods of the present disclosure include, but are not limited to, Boyden chamber assays, cell migration assays, cell invasion assays, microfluidic migration devices, in vitro scraping assays, extracellular matrix (ECM) protein assays. The methods of the present disclosure can be performed using a variety of assay platforms (e.g., 12-well, 24-well, or 96-well multiwell arrays), including "universal" trans-well platforms. Non-limiting examples of assay platforms include Cell culture inserts and insert plates, and Polycarbonate membrane cell culture inserts.
[0101] Embodiments of the present disclosure
[0102] Non-limiting embodiments of the present disclosure include:
[0103] 1. A method for determining a pharmacokinetic (PK) parameter of a molecule, the method comprising determining a measure of transcytosis of a molecule or molecules by a cell or cells under physiological pH conditions.
[0104] 2. The method of embodiment 1, wherein the PK parameter is a measure of the in vivo clearance of the molecule.
[0105] 3. The method of embodiment 1, wherein the PK parameter is a measure of the in vivo half-life of the molecule.
[0106] 4. The method of any one of embodiments 1 to 3, wherein the measure of transcytosis is the rate of transcytosis.
[0107] 5. The method of any one of embodiments 1 to 3, wherein the measure of transcytosis is a measure of the amount of a molecule or molecules that undergoes transcytosis.
[0108] 6. A method according to embodiment 1, wherein the measure of transcytosis is determined by measuring the transcytosis of a molecule or multiple molecules from a solution in a first chamber to a solution in a second chamber, wherein the first chamber and the second chamber are separated by a cell monolayer and the solution in each chamber is at physiological pH.
[0109] 7. The method of embodiment 1, wherein the cell or cells are Martin-Darby canine kidney (MDCK) cells.
[0110] 8. The method of embodiment 1 or 7, wherein the cell comprises at least one heterologous gene.
[0111] 9. The method according to embodiment 8, wherein the at least one heterologous gene is selected from the group consisting of FCGRT gene and B2M gene.
[0112] 10. The method of any one of embodiments 2 to 9, wherein the cell expresses a heterologous cell surface protein.
[0113] 11. The method of embodiment 10, wherein the heterologous cell surface protein comprises a neonatal Fc receptor (FcRn).
[0114] 12. The method of any one of embodiments 1 to 11, wherein measuring transcytosis of the molecule comprises using enzyme-linked immunosorbent assay (ELISA), liquid scintillation counting (LSC), quantitative PCR, or a fluorescence reader system.
[0115] 13. The method of any one of embodiments 1 to 12, further comprising: determining the in vivo clearance rate of the molecule based on the number of molecules measured.
[0116] 14. The method of any one of embodiments 1 to 13, wherein the molecule is one that naturally binds FcRn.
[0117] 15. The method of any one of embodiments 1 to 13, wherein the molecule is engineered to bind FcRn.
[0118] 16. The method of any one of embodiments 1 to 15, wherein the molecule is an Fc-containing molecule.
[0119] 17. The method of embodiment 16, wherein the Fc-containing molecule is a receptor Fc fusion molecule.
[0120] 18. The method of any one of embodiments 16, wherein the molecule is an antibody.
[0121] 19. The method of embodiment 18, wherein the antibody is a monoclonal antibody.
[0122] 20. The method of any one of embodiments 1 to 19, wherein the molecule is an albumin-containing molecule.
[0123] 21. The method of any one of embodiments 1 to 20, wherein the physiological pH is about 7.4.
[0124] 22. A method for measuring transcellular transport of a plurality of single molecules or a plurality of different molecules, comprising:
[0125] a) introducing a plurality of single molecules or a plurality of different molecules into a first chamber of the two chambers, wherein the first chamber is separated from the second chamber by a cell or cells, and wherein the first chamber and the second chamber each have a physiological pH; and
[0126] b) Measuring the number of molecules transcytosed from the first compartment to the second compartment.
[0127] 23. The method of embodiment 22, wherein the first chamber comprises a monolayer of cells.
[0128] 24. The method of embodiment 22 or 23, wherein the cells are Martin-Darby canine kidney (MDCK) cells.
[0129] 25. The method of any one of embodiments 22 to 24, wherein the cell comprises at least one heterologous gene.
[0130] 26. The method of embodiment 25, wherein the at least one heterologous gene is selected from the group consisting of a FCGRT gene and a B2M gene.
[0131] 27. The method of any one of embodiments 22 to 26, wherein the cell expresses a heterologous cell surface protein.
[0132] 28. The method of embodiment 27, wherein the heterologous cell surface protein comprises a neonatal Fc receptor (FcRn).
[0133] 29. The method of any one of embodiments 22 to 28, wherein measuring the number of molecules transported across the cell comprises using enzyme-linked immunosorbent assay (ELISA), liquid scintillation counting (LSC), quantitative PCR, or a fluorescence reader system.
[0134] 30. The method of any one of embodiments 22 to 29, further comprising: determining the in vivo clearance rate of the molecule based on the number of molecules measured.
[0135] 31. The method of any one of embodiments 22 to 30, wherein the molecule is one that naturally binds FcRn.
[0136] 32. The method of any one of embodiments 22 to 31, wherein the molecule is engineered to bind FcRn.
[0137] 33. The method of any one of embodiments 22 to 32, wherein the molecule is an Fc-containing molecule.
[0138] 34. The method of embodiment 33, wherein the Fc-containing molecule is a receptor Fc fusion molecule.
[0139] 35. The method of any one of embodiments 22 to 34, wherein the molecule is an antibody.
[0140] 36. The method of embodiment 35, wherein the antibody is a monoclonal antibody.
[0141] 37. The method of any one of embodiments 22 to 36, wherein the molecule is an albumin-containing molecule.
[0142] 38. The method of any one of embodiments 22-37, wherein the physiological pH is about 7.4.
[0143] 39. A method for determining the in vivo clearance rate of a molecule, comprising:
[0144] a) introducing a molecule into a first chamber of the two chambers, wherein the first chamber is separated from the second chamber by a cell or cells, and wherein the first chamber and the second chamber each have a physiological pH;
[0145] b) measuring the number of molecules transcytosed from the first compartment to the second compartment; and
[0146] c) Based on the number of molecules detected, determine the in vivo clearance rate of the molecule.
[0147] 40. The method of embodiment 39, wherein the first chamber comprises a monolayer of cells.
[0148] 41. The method of embodiment 39 or 40, wherein the cell is an MDCK cell.
[0149] 42. The method of any one of embodiments 39 to 41, wherein the cell comprises at least one heterologous gene.
[0150] 43. The method of embodiment 42, wherein the at least one heterologous gene is selected from the group consisting of a FCGRT gene and a B2M gene.
[0151] 44. The method of any one of embodiments 39 to 43, wherein the cell expresses a heterologous cell surface protein.
[0152] 45. The method of embodiment 44, wherein the heterologous cell surface protein comprises a neonatal Fc receptor (FcRn).
[0153] 46. The method of any one of embodiments 39 to 45, wherein measuring the number of molecules transported across the cell comprises using enzyme-linked immunosorbent assay (ELISA), liquid scintillation counting (LSC), quantitative PCR, or a fluorescence reader system.
[0154] 47. The method of any one of embodiments 39 to 46, wherein the molecule is one that naturally binds FcRn.
[0155] 48. The method of any one of embodiments 39 to 46, wherein the molecule is engineered to bind FcRn.
[0156] 49. The method of any one of embodiments 39 to 48, wherein the molecule is an Fc-containing molecule.
[0157] 50. The method of embodiment 49, wherein the Fc-containing molecule is a receptor Fc fusion molecule.
[0158] 51. The method of any one of embodiments 39 to 50, wherein the molecule is an antibody.
[0159] 52. The method of embodiment 51, wherein the antibody is a monoclonal antibody.
[0160] 53. The method of any one of embodiments 39 to 52, wherein the molecule is an albumin-containing molecule.
[0161] 54. The method of any one of embodiments 39-53, wherein the physiological pH is about 7.4.
[0162] 55. An assay for measuring transcellular transport of multiple molecules, comprising a first chamber and a second chamber, the first chamber and the second chamber each having a physiological pH, wherein the first chamber receives the multiple molecules, is configured to transport the molecules transcellularly to the second chamber, and the transcellular transport of the multiple molecules is measured.
[0163] 56. The assay of embodiment 55, wherein the first chamber comprises a monolayer of cells.
[0164] 57. The assay of embodiment 55 or 56, wherein the cells are MDCK cells.
[0165] 58. The assay of any one of embodiments 55 to 57, wherein the cells comprise at least one heterologous gene.
[0166] 59. The assay of embodiment 58, wherein the at least one heterologous gene is selected from the group consisting of a FCGRT gene and a B2M gene.
[0167] 60. The assay of any one of embodiments 55 to 59, wherein the cells express a heterologous cell surface protein.
[0168] 61. The assay of embodiment 60, wherein the heterologous cell surface protein comprises a neonatal Fc receptor (FcRn).
[0169] 62. The assay of any one of embodiments 55 to 61, wherein measuring the number of molecules transported across the cell comprises using enzyme-linked immunosorbent assay (ELISA), liquid scintillation counting (LSC), quantitative PCR, or a fluorescence reader system.
[0170] 63. The assay of any one of embodiments 55 to 62, further comprising: determining the in vivo clearance rate of the molecule based on the number of molecules measured.
[0171] 64. The method of any one of embodiments 55 to 63, wherein the molecule is one that naturally binds FcRn.
[0172] 65. The method of any one of embodiments 55 to 62, wherein the molecule is engineered to bind FcRn.
[0173] 66. The method of any one of embodiments 55 to 65, wherein the molecule is an Fc-containing molecule.
[0174] 67. The method of embodiment 66, wherein the Fc-containing molecule is a receptor Fc fusion molecule.
[0175] 68. The method of any one of embodiments 55 to 67, wherein the molecule is an antibody.
[0176] 69. The method of embodiment 68, wherein the antibody is a monoclonal antibody.
[0177] 70. The method of any one of embodiments 55 to 69, wherein the molecule is an albumin-containing molecule.
[0178] 71. The method of any one of embodiments 55-70, wherein the physiological pH is about 7.4.
[0179] 72. An assay system comprising:
[0180] a) a first chamber and a second chamber, wherein the first chamber and the second chamber each have a physiological pH;
[0181] b) a monolayer of cells positioned in the first compartment such that the cells can mediate transcytosis of molecules introduced into the first compartment to the second compartment; and
[0182] c) A detector for detecting the presence of the molecule in the second chamber.
[0183] 73. The assay system of embodiment 72, wherein the cells are MDCK cells.
[0184] 74. The assay system of embodiment 72 or 73, wherein the cells comprise at least one heterologous gene.
[0185] 75. The assay system of embodiment 74, wherein the at least one heterologous gene is selected from the group consisting of a FCGRT gene and a B2M gene.
[0186] 76. The assay system of any one of embodiments 72 to 75, wherein the cells express a heterologous cell surface protein.
[0187] 77. An assay system according to embodiment 76, wherein the heterologous cell surface protein comprises a neonatal Fc receptor (FcRn).
[0188] 78. The assay system of any one of embodiments 72 to 77, wherein measuring the number of molecules transported across the cell comprises using enzyme-linked immunosorbent assay (ELISA), liquid scintillation counting (LSC), quantitative PCR, or a fluorescence reader system.
[0189] Examples
[0190] The following examples are merely illustrative of the presently disclosed subject matter and should not be considered limiting in any way.
[0191] method
[0192] Test molecules
[0193] The test molecules included 53 mAbs with human clearance data, 5 Fc fusion proteins, and an additional 9 mAbs (4 charge variants, 3 glycosylation variants, and 5 FcRn binding variants). 30 mAbs were commercially available therapeutic antibodies, of which 19 (ofatumumab, vedolizumab, adalimumab, natalizumab, nivolumab, pembrolizumab, avelumab, cetuximab, palivizumab, infliximab, olatratumab, panitumumab, reslizumab, basiliximab, ikatuzumab, durvalumab, evolocumab, alirocumab, golimumab) were purchased from manufacturers. All others are produced by Genentech (South San Francisco, CA) in engineered Chinese hamster ovary (CHO) cells.
[0194] Generation and characterization of MDCK cells expressing human FcRn and β2-microglobulin
[0195] Stable cell lines were developed using methods similar to those described previously (Claypool, 2002). Martin-Darby canine kidney II (MDCK II) cells (European Collection of Authenticated Cell Cultures (ECACC), Salisbury, UK) were grown in Dulbecco's modified minimal essential medium (Thermo Fisher Scientific, Waltham, MA) containing 10% fetal bovine serum, 100 units / mL penicillin, 100 μg / mL streptomycin, and 0.292 mg / mL L-glutamine in a humidified incubator at 37°C with 5% CO2. Cells were transfected by electroporation (Lonza Nucleofection Kit L) using a modified pRK plasmid (Eaton DL et al., 1986, Biochemistry, 25(26), pp. 8343–8347) containing cDNAs of human FcRn (FCGRT (UniProtKB-P55899, FCGRTN_HUMAN) and β2m (UniProtKB-P61769, B2MG_HUMAN)) separated by a P2A sequence (Kim, JH et al., 2011, PLoS One 6(4): e18556) and under the control of a cytomegalovirus (CMV) promoter. After 3 days, cells were selected with 5 μg / mL of puromycin and expanded for two weeks.
[0196] Then, cells were sorted for clonality and FCGRT expression by fluorescence activated cell sorting (FACS) using anti-FCGRT antibody (ADM31, Aldevron, Fargo, ND) and anti-mouse PE-conjugated secondary antibody (A10543, Thermo Fisher Scientific, Waltham, MA). All clones were maintained with a constant selection agent (5 μg / mL puromycin). Based on the cell surface expression of both FCGRT and β2m assessed by flow cytometry using FITC anti-human β2m FITC-conjugated antibodies (2M2, BioLegend, San Diego, CA), the final clones were selected using the following method.
[0197] MDCK-II cells were grown to confluence and detached using a non-enzymatic cell dissociation reagent (Sigma). First, 10 cells were incubated on ice with anti-FCGRT antibody (1:100 dilution) in PBS-0.05 M EDTA 2% BSA. 6 Cells / ml were stained. After washing, cells were incubated on ice for one hour in the dark with anti-mouse PE-conjugated secondary antibodies (1:200 dilution) and anti-β2M FITC-conjugated antibodies (1:50 dilution). Samples were washed and resuspended in PBS-0.05M EDTA 2% BSA for flow cytometric analysis on BD FACSCanto II (BD Biosciences, San Jose, CA).
[0198] Transcytosis assay
[0199] Cells were cultured at 1 x 10 in high glucose DMEM cell growth medium supplemented with 10% FBS, 100 units of penicillin / streptomycin, and 5 μg / mL puromycin. 5 Cells were plated at a density of 10 cells / well in a 96-well Trans-well plate (Corning Costar, Acton, MA, USA) with 100 μL and 200 μL of culture medium in the inner and outer chambers, respectively. The cells were used for the experiment the day after plating. The culture medium in the inner chamber was removed, and the test molecule was added to a final concentration of 100 μg / mL (0.67 μM) and incubated in a tissue culture incubator at 37°C for 24 hours. During the last 90 minutes of the 24-hour assay incubation, Lucifer Yellow (Lucifer Yellow CH, dilithium salt; Sigma Aldrich; St. Louis MO) prepared in cell growth medium was added. The culture medium was collected from the outer chamber, and the amount of transcytosis molecule ( Figure 1). The level of passive passage of Lucifer Yellow during the assay was calculated by dividing the fluorescent signal in the sample from the outer chamber by the fluorescent signal in the inner chamber. Transcytosis results from wells that exhibited more than 0.1% passive passage of Lucifer Yellow in the outer chamber were discarded.
[0200] The output of the assay is the concentration of the transcytotic molecule in the culture medium of the outer chamber (ng / mL), and the reportable value of the assay is the average concentration of 2 replicate wells from the same plate. In certain embodiments, the output of the assay can be a measure of the transcytotic rate or a measure of the relative transcytotic effect of the transcytotic molecule.
[0201] Quantification of transcytosis
[0202] 96-well microtiter plates were coated overnight at 2-8°C with 100 μL of goat anti-human IgG-F(ab)' (Jackson ImmunoResearch Laboratories, West Grove, PA) at 1 μg / mL in sodium carbonate (pH 9.6). After washing with PBS / 0.05% polysorbate-20, the plates were incubated with 200 μL of blocking buffer (PBS / 0.5%; BSA / 0.1%; casein / 0.05%; P20 / 0.05%; Proclin300) at room temperature for 2 hours with gentle agitation. After washing, 100 μL of serially diluted assay standards, controls, or samples in assay diluent (PBS / 0.5%; BSA / 0.05%; P20 / 0.05%; Proclin300) were added to the plates ( Figure 1 ). After incubation at room temperature for another hour under gentle agitation, the plate was washed again and then incubated with 100 μL of goat anti-human IgG-Fc (Jackson ImmunoResearch Laboratories, West Grove, PA) conjugated to HRP at a dilution of 1:10000 in the assay diluent. The plate was incubated for 1 hour under gentle agitation, and after washing, 100 μL of freshly mixed 3,3',5,5'-tetramethylbenzidine (TMB) solution (Kirkegaard & Perry Laboratories, Gaithersburg, MD) was added. The color was developed for 15 minutes without agitation, and the reaction was terminated by adding 100 μL of 1M H3PO4. The absorbance was read at the reference wavelengths of 450nm and 650nm on a Spectra Max I3 plate reader (Molecular Devices Corporation, CA), and the data was processed using the SoftmaxPro software provided by the manufacturer. Interpolation was performed from the four-parameter fit of the standard curve on the same plate to obtain the concentration of the test antibody in the sample.
[0203] For Fc fusion proteins, the above procedure was followed, with the test molecule captured by an antibody that specifically binds to the protein and detected by anti-human IgG-F(ab)' conjugated to HRP.
[0204] BV ELISA
[0205] A 1% baculovirus particle suspension was prepared in coating buffer (0.05 sodium carbonate, pH 9.6), 25 μL was added to each well of a 384-well plate (Nunc-Immuno plate MaxiSorp surface, catalog number 464718), and incubated overnight at 4°C. The wells were blocked with 50 μL of assay buffer (PBS containing 5% BSA and 10 PPM Proclin) at room temperature for 1 hour under gentle shaking. After washing the wells three times with 100 μL of wash buffer (PBS), 25 μL of samples prepared in assay buffer were loaded in duplicate and incubated at room temperature for 1 hour under gentle shaking. The plate was washed six times with 100 μL of wash buffer, and 25 μL of goat anti-human FcRn fragments (Jackson ImmunoResearch) specifically conjugated to horseradish peroxidase were added to each well at a concentration of 10 ng / mL in assay buffer and incubated at room temperature for 1 hour under gentle shaking. The wells were washed six times with 100 μL of wash buffer, 25 μL of TMB (Moss, Inc., catalog number TMBE-1000) substrate was added to each well with gentle shaking at room temperature for 15 minutes, 25 μL of 1 M phosphoric acid was added to each well to stop the reaction, and the absorbance at 450 nm was measured using a plate reader.
[0206] BLI-based mAb-FcRn interaction assessment
[0207] Octet RED (PALL / ForteBio) was used for all FcRn in vitro assays, which were performed at 30°C in 96-well black solid plates (Greiner Bio-One, 655900). Initially, FcRn was fixed to a nickel-nitrotriacetic acid coated biosensor (ForteBio, 18-0029) for 180 seconds at an optimal concentration. After the baseline step, the binding rate of mAb-FcRn was determined when the biosensor with immobilized FcRn was exposed to mAb samples in PBS adjusted to pH 6.0 with HCl for 30 seconds. Prior to analysis, all antibodies were dialyzed into PBS at pH 6.0, diluted to 100 mg / mL in PBS at pH 6.0, and used in a volume of 200 mL. Each assay was performed five times in parallel on a specific mAb. Data analysis was performed using software version 7.0 (PALL, ForteBio).
[0208] pI determination by imaging capillary isoelectric focusing
[0209] As previously described (Li et al., 2014), imaged capillary isoelectric focusing (icIEF) was performed on an iCE280 analyzer (ProteinSimple, Toronto, ON). The anolyte and catholyte were 80 mM phosphoric acid and 100 mM NaOH, respectively, each prepared with 0.1% methylcellulose. mAb samples were prepared in water containing carboxypeptidase and incubated at 37°C for 20 minutes to remove C-terminal lysine residues. An amphoteric electrolyte mixture consisting of 3.1% (v / v) Pharmalytes (GE Life Sciences), 2.5 M urea, 0.1% (v / v) methylcellulose, and pI 5.5 and 9.77 markers (Protein Simple) was combined with the treated antibody to a final concentration of 0.25 mg / mL. The electrophoretogram was imaged at 280 nm using an optical absorption detector.
[0210] Cell binding assay by flow cytometry
[0211] Cells were stained with test molecules at a concentration of 100 μg / mL in FACS buffer (PBS / 1% BSA / 2mM EDTA / 0.1% sodium azide) and incubated on ice for one hour. After washing with FACS buffer, cells were stained with PE-conjugated mouse anti-human IgG Fc secondary antibodies (Southern Biotech, Birmingham, AL) on ice for 1 hour. Cells were washed and fixed with fixation buffer (BD Biosciences, San Jose, CA). The fluorescence intensity of stained cells was measured using a FACSCanto II flow cytometer (BD Biosciences; San Jose, CA), and data were analyzed using FlowJo software (TreeStar; Ashland, OR).
[0212] PK study of X-Fc sialylated variants in mice
[0213] A single IV bolus dose of X-Fc variants (1, 5, 8, 12 or 15) was administered to CD1 mice at a dose of 1 mg / kg. Serum samples (n=4 per time point) were collected and analyzed for drug concentration at various time points up to 21 days after administration. Drug concentrations in serum were measured using validated ELISA assays. Pharmacokinetic parameters were estimated using serum concentration-time data from individual animals using non-compartmental sparse analysis in Phoenix WinNonlin Version 6.4.0.768 (WinNonlin 6.4; Pharsight Corporation, Mountain View, CA).
[0214] The total antibody concentration in mouse serum was measured by using the Gyros technology platform (Gyros US Inc., Warren, NJ) and a universal PK assay ELISA. The assay uses biotinylated sheep anti-human IgG antibodies as capture and uses sheep anti-human IgG conjugated with Alexa Fluor-647 as detection. The minimum dilution for the assay is 1:10. For mouse serum, the standard curve range for the assay is 0.03 to 30 μg / mL.
[0215] Example 1: Development and characterization of a neutral pH FcRn-mediated transcytosis assay
[0216] MDCK cell lines were transfected with human B2M (B2M) and FcRn heavy chain (FCGRT) genes. Stable cells expressing both genes were isolated by FACS sorting, and cloned cell lines (MDCK-hFcRn; 305-6) (Fig. 2) expressing high levels of FCGRT and B2M on the cell surface were selected to further develop FcRn-dependent transcytosis assays. In order to minimize potential assay bias / artifacts and better simulate physiological conditions, the molecules tested in the assay were not labeled, and assays were performed in growth media at physiological pH.
[0217] In this assay, cells are grown to confluence on the filter membrane of the trans-well, the test molecules are added to the growth medium in the inner chamber, and after incubation, the molecules transported through the cells and released into the medium in the outer chamber are quantified by ELISA. The assay has been extensively optimized in terms of seeding density, trans-well plate format, loading concentration, assay medium, and assay duration. Since the assay medium contains fetal bovine serum albumin (BSA), which has been shown to bind to human FcRn in the presence of IgG and form a trimolecular complex (Chaudhury C. et al., 2003, J. Exp. Med. 197, 315–322), it is expected that human FcRn will attract both the test antibody and BSA in this assay. Compared with the medium containing BSA, alternative assay medium containing different amounts of human serum albumin instead of BSA has almost no difference in transcytosis readings. Due to operational considerations, the assay is performed in normal growth medium containing FBS / BSA.
[0218] The functional integrity of MDCK-hFcRn cells grown on the filters was monitored by measuring the transepithelial electrical resistance (TEER; Srinivasan B. et al., 2015, J Lab Autom 20(2):107-126). Before the assay, the TEER of the monolayer was typically between 250 and 300 Ω*cm2 range, which is a characteristic range of polarized MDCK II cells (Tesar DB et al., 2006, Traffic 7(9): 1127-1142). In addition, the barrier integrity (leakage) of the monolayer was monitored during the assay by incorporating Lucifer Yellow and test molecules in the inner chamber as described in the Methods.
[0219] Example 2: Correlation between human in vitro transcytosis efficiency and in vivo clearance of mAbs
[0220] To evaluate the potential utility of this assay in determining or predicting the in vivo PK behavior of mAbs, 53 mAbs, including 30 commercially available therapeutic antibodies and 23 clinical candidate antibodies, were tested in this assay. The potential correlation between the transcytosis output of mAbs and their reported clearance rates in humans was analyzed. These molecules were selected based on the availability of clinical-grade materials and in vivo clearance data in humans. In addition to the transcytosis assay, two other in vitro assays were performed on some molecules: the BV ELISA and the human FcRn binding assay based on biolayer interferometry (BLI). The BV ELISA measures nonspecific binding to baculovirus particles as an indicator of the general nonspecific binding properties of mAbs and has been reported to be able to identify antibodies with an increased risk of rapid clearance in cynomolgus monkeys et al., 2012, (2012), MAbs 4(6):753-760). A BLI-based FcRn binding assay has been used to generate combined FcRn association rates at pH 6.0 and dissociation rates at pH 7.4, which showed strong correlation with the half-life of five mAbs in humans and human FcRn transgenic mice (Souders CA et al., 2015, MAbs 7(5):912-921).
[0221] Table 1 lists the results of this study, which also includes the clearance rates of the test molecules in both humans and cynomolgus monkeys (cyno). The mean transcytosis output of the test group was 5.4 ng / mL, the median was 4.5, and the range was 2.6 to 14.9, which reflects that the loading material in the inner chamber was about 0.005% (100 μg / mL) on average. The corresponding means and medians / ranges of FcRn binding affinity (Kd in μM) and BV ELISA scores at pH 6.0 are as follows: 0.63, 0.54 / 0.25 to 1.8; and 0.25, 0.06 / 0.0.038 to 3.916, respectively. The human clearance rates of commercially available mAb drugs were obtained from the drug's prescribing information or published reports; the clearance rates of clinical-stage mAbs were from clinical studies performed by Genentech or published reports. The cynomolgus monkey clearance rate was from cynomolgus monkey studies conducted by Genentech. The mean, median / range of clearance rates in humans was 5.0, 4.1 / 1.4 to 14.1 mL / Kg / day, while in cynomolgus monkeys it was 6.8, 4.9 / 3.0 to 15.8 mL / Kg / day. It appears that the values of all parameters are distributed over a range of at least 5-fold, which indicates that the panel of mAbs tested in this study has considerable diversity.
[0222] As shown in FIG3A , a clear correlation trend was observed between transcytosis output and clearance values with a fitted linear regression R-squared value of 0.8. Antibodies with higher clearance rates in humans are reported to generally show higher transcytosis output in this assay. It is noteworthy that the observed correlation was not affected by subgrouping test molecules based on heavy and light chain subclasses, target properties (soluble or membrane-bound), mechanism of action (agonistic, antagonistic or cytotoxic), or route of administration. On the other hand, there was no clear correlation between clearance rate and FcRn binding at pH 6.0 via BLI or BV ELISA ( FIG3B , FIG3C ).
[0223] In general, cynomolgus monkey PK provides the most translatable model for determining or predicting the human PK of mAbs. The correlation between transcytosis output and cynomolgus clearance may provide additional validation for the usefulness of this assay as a deterministic or predictive tool for PK. Cynomolgus clearance data were obtained for 25 mAbs in the group and analyzed for correlation with human clearance rates or transcytosis efficiency values. As shown in Figure D, a trend toward association was observed between transcytosis efficiency and cynomolgus clearance, and the degree of correlation, as judged by the R-squared value, appeared to be similar to that between cynomolgus monkey and human clearance (Figure 3D). However, due to some “outliers,” the R-squared value was approximately 0.6. The two most obvious outliers in the cynomolgus clearance versus transcytosis plot (Figure 3D) are aNRP1 and pertuzumab; the former is known for its inconsistency with human clearance ( Figure 3E ), the latter of which may bind to MDCK cells due to cross-reactivity with canine epidermal growth factor receptor 2 (Fazekas, 2016). Removing these two molecules increased the R-squared value of the linear regression fit to 0.75 in Figure 3D and Figure 3E 0.76 of them.
[0224] Table 1
[0225]
[0226]
[0227] ND = not completed; NA = not available; ROA = route of administration; M = membrane bound; S = soluble; SC = subcutaneous; IV = intravenous; IM = intramuscular.
[0228] To demonstrate the dependence on FcRn interaction in the observed correlation between transcytosis output and clearance, 12 mAbs (10 from the set of human clearance data) were randomly selected based on the different transcytosis outputs observed in the experiment and tested in a similar transcytosis assay using parental MDCK cells. The resulting transcytosis values were analyzed for trends in correlation with their clearance rates (Figure 4A) and compared with the results measured using MDCK-hFcRn cells (Figure 4B). As shown in Table 3 and Figure 4A, transcytosis values in MDCK cells were generally less than 10% of the results of the assay using FcRn-transfected cells and had no clear correlation with the clearance rate in humans. On the other hand, in MDCK-hFcRn cells tested using the same set of mAbs, transcytosis had a strong correlation with clearance (Figure 4B). The results of this study support that the interaction between FcRn and the tested antibodies is not only involved in promoting transcytosis in this assay, but also directly contributes to their correlation with clearance in humans.
[0229] Example 3: Effect of cell binding on mAb transcytosis
[0230] It is known that nonspecific off-target binding can affect the PK of mAb drugs (Boswell et al., 2010, Bioconjug. Chem. 21, 2153-2163). In this assay, the transcytosis of the test molecule involves the binding and internalization of MDCK-hFcRn cells. The test molecule can bind to the cell via nonspecific interactions or specific binding to cell surface FcRn at physiological pH, both of which may affect the output of transcytosis. In order to evaluate the effect of cell binding on transcytosis, the selective mAb was incubated with both transfected MDCK-hFcRn and untransfected MDCK cells, and the bound antibody was detected by flow cytometry with fluorescently conjugated mouse anti-human IgG-Fc. The degree of binding to the cell is represented by the geometric mean fluorescence intensity, and the results are listed in Table 2. It appears that with a few exceptions, most differences in intracellular mAb binding to either cell line were minimal, suggesting that FcRn expression does not drastically alter Ab binding behavior to MDCK cells in most cases due to minimal binding to FcRn at physiological pH. No clear correlation was observed between cell binding and transcytosis export ( Figure 4C ).
[0231] Interestingly, both anti-HER2 antibodies (trastuzumab and pertuzumab) showed enhanced binding to MDCK cells, whether or not the cells had transfected human FcRn (Table 2). Human HER2 has been reported to have a high degree of homology to its canine counterpart, and both trastuzumab and pertuzumab can be used to treat canine breast cancer (Fazekas, 2016). Therefore, the observed binding of these two molecules to the cells can be explained by cross-reactivity with canine epidermal growth factor receptor 2 expressed on MDCK cells. In addition, anti-gD showed increased binding to MDCK-hFcRn, but not to non-transfected MDCK cells, indicating that it specifically binds to human FcRn on MDCK-FcRn cells at physiological pH. Again, the increased binding to MDCK-FcRn cells did not translate into increased transcytosis in MDCK-FcRn cells. The observed binding may not directly lead to internalization of the complex; instead, internalized anti-gD is preferentially recycled back to the endosome or directed to lysosomes for degradation and is therefore not trafficked via the transcytosis pathway. Finally, of the 12 mAbs tested, two mAbs (basiliximab and mAb 12) that exhibited increased transcytosis and faster clearance also showed elevated binding to both cell lines. This suggests that both molecules may interact nonspecifically with the MDCK cell membrane, leading to increased transcytosis in the assay and potentially playing a role in their reported rapid clearance in humans.
[0232] Table 2
[0233]
[0234] In summary, the results of this study suggest that while binding to cells via specific or nonspecific interactions may affect transcytosis, the output of this assay is not determined solely by binding; other influencing factors, such as cellular uptake / internalization, interaction with FcRn in endosomes, and sorting / transport in cells, are relevant to the overall outcome. MFI = geometric mean fluorescence intensity.
[0235] Example 4: Effect of Charge on mAb Transcytosis
[0236] Charge is one of the main factors that determine how mAbs interact with negatively charged components on the cell surface. It has been shown that changes in charge can alter the PK behavior of mAbs: mAbs with higher pI or higher positive Fv charge are cleared faster than their counterparts with lower pI / positive charge (Igawa, T. et al., 2010, Protein Eng Des Sel 23(5):385-392; Boswell et al., Chem. 21, 2153–2163 (2010). 10; Bumbaca Y. et al., 2015, J Biol Chem 290(50):29732-29741). It is assumed that higher positive charge will lead to faster nonspecific clearance by increasing nonspecific binding, which may be due to greater electrostatic interactions with negatively charged extracellular matrix, while lower positive charge will lead to reduced nonspecific binding and slower nonspecific clearance.
[0237] In order to understand the effect of charge on mAb transcytosis, two groups of mAbs with designed Fv charge variants whose PK behavior has been evaluated in several preclinical species were tested in our assay (Bumbaca Y. et al., 2015, J Biol Chem 290 (50): 29732-29741). These charge variants are based on anti-lymphotoxin α (anti-Ltα) and humAb4D5-8 (anti-HER2), one of which has a higher positive charge Fv (anti-LTα+3 and anti-HER2+3) and the other has a lower positive charge Fv (anti-Ltα-4 and anti-HER2-4). In the reported studies, both variants with higher Fv positive charge showed faster nonspecific clearance compared to the parent molecule, while those with lower positive charge showed similar or slower clearance (Bumbaca Y. et al., 2015, J Biol Chem 290 (50): 29732-29741). The correlation between Fc charge and clearance was observed in all preclinical species tested, including cynomolgus monkeys, mice, and rats; the lack of species dependence supports the hypothesis of nonspecific electrostatic interactions between positively charged mAbs and negatively charged cellular components. As shown in Table 3, the order of transcytosis values for the two groups of charge variants follows the same trend as the degree of Fv charge and the clearance rates observed in cynomolgus monkeys. Both of the more positively charged variants (anti-LTα+3 and anti-HER2+3) showed higher transcytosis outputs compared to the parent molecule, while the two lower charged molecules showed lower transcytosis outputs. It seems that the transcytosis output correctly reflects the observed ordering of clearance rates for the two groups of charge variants. The results of this study indicate that changes in mAb charge affect the transcytosis readout in our assay just as it affects the PK of the mAb, and that our assay is able to reflect the effect of charge on clearance.
[0238] Table 3
[0239]
[0240] To better understand the general impact of electrostatic interactions on mAb clearance in humans, the combined charge of Fv (vL+vH) was calculated for 19 mAbs (out of the 50 mAbs tested) and their correlation with clearance was analyzed. In addition, the pI of these molecules was measured by icIEF and similar analyses were performed. As shown in Figures 5A and 5B, although a trend of correlation between the clearance rate in humans and the pI or Fv combined charge values was observed, the strength of the correlation appeared to be weak, as confirmed by the relatively low R-squared values (less than 0.25). On the other hand, the correlation between clearance and transcytosis remained strong in this mAb subgroup (R-squared values greater than 0.8; Figure 5C ). It appears that, although substantial changes in charge are expected to modulate the transcytosis behavior of mAbs, the output of the assay is still determined by the combined effects of multiple factors other than charge.
[0241] Example 5: Effect of glycosylation on transcytosis of Fc-containing molecules
[0242] The glycosylation pattern of mAb or Fc fusion protein can significantly affect its PK and PD behavior (Higel F. et al., 2016, Eur J Pharm Biopharm 100: 94-100). It has been shown that mAbs carrying more than 99% high mannose N-glycans (Man5 or Man8 / 9) show faster clearance in preclinical species compared with controls with typical glycosylation patterns (Yu M et al., 2012, MAbs 4 (4): 475-487), and Fc fusion proteins with extensive sialylation have reduced clearance compared with Fc fusion proteins with low sialylation in the fusion partner (Stefanich EG et al., 2008 J Pharmacol Exp Ther 327 (2): 308-315). It is hypothesized that mAbs carrying high mannose glycans are bound and cleared by the mannose receptors most prominently expressed on immune cells (Lee SJ et al., 2002, Science 295: 1898–1901), whereas Fc fusion proteins (not sialylated) with exposed terminal galactose are bound and cleared by asialoglycoprotein receptors expressed in the liver (Stockert RJ, 1995, Physiol. Rev. 75: 591–609).
[0243] To investigate the effect of glycosylation on transcytosis of mAbs and Fc-fusion proteins, two groups of molecules with different glycosylation patterns were tested. Variants of the glycoform of ocrelizumab (2H7) included one variant devoid of Fc N-linked glycans (2H7-DG) by in vitro deglycosylation and another variant carrying more than 99% mannosyl 5 glycans (2H7-Man5). Another group of variants was based on X-Fc, a fusion protein composed of human glycoprotein X and human IgG1 Fc; the five variants of X-Fc carried different levels of sialylation, representing 1, 5, 8, 12, and 15 moles of sialic acid per mole of X-Fc (X-Fc1, X-Fc5, X-Fc8, X-Fc12, and X-Fc15, respectively). The clearance rates of 2H7 and 2H7-Man5 were obtained from previously published studies (Yu M et al., 2012, MAbs 4(4):475-487); the clearance rates of X-Fc sialylated variants were generated by internal mouse studies. Although there is no clearance data for 2H7-DG, it is reported that the removal of Fc N-glycans does not induce discernible changes in its half-life (Tao MH and Morrison SL, 1989, J Immunol 143(8):2595-2601). In addition, atezolizumab, which does not carry Fc N-glycans due to the N297G mutation, shows normal PK characteristics in humans (prescription information and Table 1). As shown in Table 4, compared with 2H7, 2H7-DG exhibits similar transcytosis, while 2H7-Man5 exhibits a 2-fold increase in transcytosis, the former predicting similar clearance, while the latter predicting faster clearance, both of which are consistent with the expected / observed order of their in vivo clearance rates. Similarly, five X-Fc variants showed reduced levels of transcytosis in an order consistent with a reduction in the amount of terminal galactose exposed due to increased sialylation; the predicted ranking of clearance rates for these sialylation variants was consistent with the clearance data observed from mouse studies.
[0244] To explore the potential impact of glycosylation on FcRn binding and / or non-specific interactions with cells, two sets of glycosylation variants were tested for FcRn binding affinity and relative binding to MDCK-hFcRn cells. The deglycosylated molecule (2H7-DG) showed no discernible differences in binding to FcRn and cells compared to 2H7. On the other hand, the mannose-5 glycoform (2H7-Man5) showed a slight increase in binding to MDCK cells and a moderate increase in binding to FcRn at pH 6.0; however, it did not show an increase in transcytosis in MDCK cells and had no additional increase in binding to MDCK-FcRn cells. Similar to the 2H7man-5 glycoform, the X-Fc sialylated variant showed no clear correlation between transcytosis in MDCK-hFcRn cells and cell binding or transcytosis in MDCK cells. However, in contrast to 2H7-Man5, which showed increased FcRn binding and increased transcytosis, the X-Fc sialylated variants showed a trend toward increased FcRn binding that was negatively correlated with transcytosis output in MDCK-FcRn cells. This suggests that glycosylation may affect FcRn binding and transcytosis differently depending on the glycan species. Of note, the lack of a clear increase in binding of 2H7-Man5 and X-Fc-SA1 to MDCK cells suggests that the increase in transcytosis was not due to binding to specific receptors such as the mannose receptor or asialoglycoprotein receptor, which are known to be involved in the catabolism of these IgG glycoforms; however, we have no direct evidence to confirm the presence of such receptors in MDCK cells.
[0245] Table 4
[0246]
[0247] Example 6: Effect of extreme FcRn binding on transcytosis of mAbs
[0248] It has been shown that improving the binding affinity of FcRn through genetic engineering affects the half-life of therapeutic antibodies and Fc fusion proteins (Ward ES et al., 2015, Mol Immunol 67 (2Pt A): 131-141). Therefore, it is meaningful to explore the transcytosis behavior of mAbs carrying engineered mutations that substantially change the binding affinity of FcRn. Two groups of molecules were tested for transcytosis in both parental MDCK and MDCK-hFcRn cells. The first group included anti-VEGF (humanized IgG1 mAb) and anti-VEGF-QA (which carries T307Q / N434A mutations, which increases FcRn binding by nearly 10 times) (Yeung YA et al., 2010, Cancer Res 70 (8): 3269-3277). The second group includes humanized herpes simplex virus glycoprotein D-specific IgG1 antibody, i.e., anti-gD (WT), and its two FcRn binding variants, i.e., anti-gD-HAHQ, which carries H310A / H435Q mutations, thereby reducing FcRn binding activity (Kenanova V. et al., 2005, Cancer Res 65(2):622-631), and anti-gD-YTE, which carries M252Y / S254T / T256E mutations, which can increase its FcRn binding by more than 10 times (Dall'Acqua, 2006). As shown in Table 5, significant transcytosis of all five molecules was clearly observed in MDCK-hFcRn cells, among which anti-gD-HAHQ showed the lowest transcytosis value, which may be due to its inability to bind to FcRn. However, in contrast to the results for the mAb group where increased endocytosis was associated with increased clearance rates (fast clearance), both anti-VEGF-QA and anti-gD-YTE, which exhibited slower in vivo clearance rates compared to their wild-type counterparts, showed increased transcytosis. Molecules with extreme FcRn binding affinities may behave differently in this assay due to their different responses to the sorting mechanisms that control the recycling and transcytosis pathways.
[0249] Interestingly, while most molecules showed low levels of transcytosis in MDCK cells, below or slightly above the detection limit of ELISA, 0.3 ng / mL, anti-gD-YTE showed dramatic transcytosis levels exceeding 1 ng / mL, presumably independent of FcRn. The significant differences in transcytosis output observed between the two cell lines support that transcytosis observed in MDCK-hFcRn cells is primarily driven by FcRn and that the assay is specific for molecules containing the intact Fc domain of IgG capable of interacting with FcRn. Notably, although both anti-VEGF-QA and anti-gD-YTE showed an 8- to 10-fold increase in FcRn binding activity compared to their wild-type counterparts, the increase in transcytosis was rather modest, with a less than two-fold increase in transcytosis for anti-VEGF-QA and a slightly more than two-fold increase in transcytosis for anti-gD-YTE.
[0250] Table 5
[0251]
[0252] All publications, patents, and other references cited herein are incorporated by reference into this disclosure in their entirety.
Claims
1. A method for determining the in vivo clearance rate of a molecule that interacts with FcRn, comprising: a) introducing the molecule into a first chamber, wherein the first chamber is separated from a second chamber by a cell or cells, and wherein the first chamber and the second chamber each have a physiological pH of about 7.4; b) measuring the number of molecules transcytosed from the first compartment to the second compartment; and c) determining the in vivo clearance rate of said molecule based on the number of said molecules measured, wherein the first chamber comprises a monolayer of cells; wherein the cells express a heterologous cell surface protein; and the heterologous cell surface protein comprises a neonatal Fc receptor (FcRn); The method described herein is not a diagnostic method or a therapeutic method.
2. The method of claim 1, wherein the cell is an MDCK cell.
3. The method of claim 1 or 2, wherein the cell comprises at least one heterologous gene. The method according to claim 3 , wherein the at least one heterologous gene is selected from the group consisting of FCGRT gene and B2M gene.
5. The method according to any one of claims 1 to 4, wherein step b) comprises using an enzyme-linked immunosorbent assay (ELISA), liquid scintillation counting (LSC) or a fluorescence reader system.
6. The method of any one of claims 1 to 5, wherein the molecule is a molecule that naturally binds to FcRn.
7. The method of any one of claims 1 to 5, wherein the molecule is engineered to bind FcRn.
8. The method of any one of claims 1 to 7, wherein the molecule is an Fc-containing molecule.
9. The method of claim 8, wherein the Fc-containing molecule is a receptor Fc fusion molecule.
10. The method according to any one of claims 1 to 9, wherein the molecule is an antibody. The method of claim 10 , wherein the antibody is a monoclonal antibody.
12. The method according to any one of claims 1 to 11, wherein the molecule is an albumin-containing molecule.
13. An assay system for determining the in vivo clearance of molecules that interact with FcRn by measuring the transcellular transport of multiple molecules, the assay system comprising a first chamber and a second chamber, both of which have a physiological pH of about 7.4, wherein the first chamber receives multiple molecules and is configured to transport the molecules transcellularly to the second chamber, and the transcellular transport of the multiple molecules is measured, wherein the first chamber contains a monolayer of cells, wherein the cells express heterologous cell surface proteins; and the heterologous cell surface proteins contain neonatal Fc receptor (FcRn).
14. The assay system of claim 13, wherein the cells are MDCK cells.
15. The assay system according to any one of claims 13 or 14, wherein the cells comprise at least one heterologous gene.
16. The assay system according to claim 15, wherein the at least one heterologous gene is selected from the group consisting of FCGRT gene and B2M gene.
17. The assay system of any one of claims 13 to 16, wherein measuring the number of molecules transported across cells comprises using an enzyme-linked immunosorbent assay (ELISA), liquid scintillation counting (LSC), or a fluorescence reader system.
18. The assay system according to any one of claims 13 to 17, further comprising: The in vivo clearance rate of the molecule is determined based on the number of the molecule measured.
19. The assay system according to any one of claims 13 to 18, wherein the molecule is a molecule that naturally binds to FcRn.
20. The assay system of any one of claims 13 to 18, wherein the molecule is engineered to bind FcRn.
21. The assay system of any one of claims 13 to 20, wherein the molecule is an Fc-containing molecule.
22. The assay system of claim 21, wherein the Fc-containing molecule is a receptor Fc fusion molecule.
23. The assay system according to any one of claims 13 to 22, wherein the molecule is an antibody.
24. The assay system of claim 23, wherein the antibody is a monoclonal antibody.
25. The assay system according to any one of claims 13 to 24, wherein the molecule is an albumin-containing molecule.
